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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.03.002VIPoma is an exceedingly unusual neuroendocrine neoplasm that autonomously secretes vasoactive intestinal
polypeptide (VIP). Its reported incidence is approximately 1 per 10 million individuals per year. Herein, we
report the case of sporadic pancreatic VIPoma in a 47-year-old male who presented with a six-month history
of chronic, plentiful, watery diarrhea. On physical examination, the patient looked sick, lethargic and had signs
of dehydration. Laboratory investigations revealed high VIP hormone level (989 pg/mL), hypokalemia,
hypercalcemia, hyperglycemia, high blood urea nitrogen, high creatinine, and metabolic acidosis on arterial
blood gas. Contrast-enhanced computed tomography (CT) scan showed a 3.1 · 3.3 · 4.7 cm, well-defined,
enhancing lesion involving the pancreatic tail with a cystic component. Moreover, a 5.7 · 6.1 · 6.8 cm
metastatic hepatic lesion was identified. The patient underwent distal pancreatectomy with splenectomy,
hepatic lesion resection, and lymph node dissection. Histopathological and immunohistochemical examination
of the pancreatic and hepatic lesions revealed neuroendocrine tumor (VIPoma). Postoperatively, the patient
received radiofrequency ablation for the hepatic lesion. A post-operative six-month follow-up showed
significant symptomatic relief, reduced VIP hormone level (71 pg/mL) and normalized electrolyte and acid–base
profiles. However, a magnetic resonance imaging (MRI) scan showed a small residual metastatic liver lesion
which was considered for hepatic artery embolization (HAE). The patient is still alive with a residual hepatic
disease at 18 months. We also present a brief literature review on VIPoma.CASE REPORT
A47-year-old male presented with a six-monthhistory of chronic, plentiful, watery diarrhea.The patient declared around 12–15 loose
bowel movements and estimated average volume loss
of nearly 2.5–3.5 L per day. Furthermore, diarrhea
was uniformly continuous, unstopped by fasting,
non-responding to loperamide (anti-diarrheal agent)
and free of mucus, fat or blood. Diarrhea was associ-
ated with abdominal bloating (indigestion), nausea,
vomiting, facial redness, muscle weakness, palpitation,
and unintentional weight loss of approximately 13 kg.
The patient denied any history of recent travel to
tropical areas, food intoxication, laxative abuse, herbaluse, visual ﬁeld defects. Past medical history was
remarkable for hypertension controlled on losartan
medication. Past surgical history was unremarkable.
On physical examination, the patient looked sick,
lethargic, and had signs of severe dehydration such
as dry skin, decreased skin turgor, delayed capillary
reﬁll, and sunken eyes. Vital signs were remarkable
for low blood pressure (84/55 mmHg), tachycardia
(121 beats/min), and tachypnea (23 breaths/min).
Initial laboratory ﬁndings revealed high vasoactive
intestinal polypeptide (VIP) hormone level (989 pg/
mL), hypokalemia (2.6 mmol/L), hypercalcemia
(3.2 mmol/L), hyperglycemia (172 mg/dL), high
blood urea nitrogen (45 mg/dL), high blood creati-
nine (1.4 mg/dL), and metabolic acidosis on arterial109
Fig. 1. A cross-sectional, contrast-enhanced computed tomography (CT)
scan showed a 3.1 · 3.3 · 4.7 cm, well-defined, enhancing lesion
involving the pancreatic tail with a cystic component (red arrow).
Moreover, a 5.7 · 6.1 · 6.8 cm, focal, well-defined, metastatic lesion
with a cystic component involving the left hepatic lobe was identified
(yellow arrow). No other sites of distant metastases were recognized.
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case report SPORADIC PANCREATIC VIPOMAblood gas (pH: 7.15, bicarbonate level: 6.4 mmol/L).
Complete blood count, hepatic, coagulation, prolactin,
thyroid and parathyroid proﬁles were unremarkable.
Stool for ova and parasites, culture and sensitivity
were negative.
In view of possible VIPoma and resultant severe
dehydration, electrolyte and acid–base imbalances,
the patient was admitted for further workup. On
admission, patient was started on ﬂuid replenishment,
electrolyte replacements and octreotide administration
for symptomatic control of diarrhea. The patient
showed marked improvement.
A contrast-enhanced computed tomography (CT)
scan showed a 3.1 · 3.3 · 4.7 cm, well-deﬁned,
enhancing lesion involving the pancreatic tail with a
cystic component. Moreover, a 5.7 · 6.1 · 6.8 cm,
focal, well-deﬁned, metastatic lesion with a cystic
component involving the left hepatic lobe was identi-
ﬁed. No other sites of distant metastases were recog-
nized (Fig. 1). CT-guided needle-core biopsies from
the pancreatic and hepatic lesions were obtained,
and histopathological and immunohistochemical eval-
uations were consistent with neuroendocrine tumor
(VIPoma).
The patient underwent distal pancreatectomy with
splenectomy, hepatic lesion resection, and lymph node
dissection (pancreatic, celiac and porta hepatic lymph
nodes). Macroscopic and microscopic examination of
lymph node dissections showed unremarkable pathol-
ogy and were negative for malignancy.HemGrossly, the distal pancreatectomy measured
12 cm in the maximum diameter. Cut-surface showed
a 2.7 · 2.9 · 4.6 cm, irregular, white-tanned and ﬁrm
mass involving the pancreatic tail. Microscopically, the
tumor was made up of solid sheets/cords of relatively
uniform, intermediate-sized cuboidal cells with cen-
trally located nuclei, stippled chromatin, and delicately
granular eosinophilic cytoplasm (Fig. 2A and B).
Mitosis was depicted as 4 mitoses per 10 high power
ﬁelds (HPF). There was proof of vascular and peri-
neural invasion. Surgical excision borders were
tumor-free. Immunohistochemically, tumor cells
stained positive for chromogranin A, synaptophysin,
VIP, somatostatin and Ki-67 (17%) (Fig. 3A–E).
The hepatic lesion was shown to be a metastatic
VIPoma lesion. Collectively, according to the clinical,
laboratory, radiological, histopathological and immu-
nohistochemical proﬁles, a ﬁnal diagnosis of primary
functioning neuroendocrine tumor (VIPoma), World
Health Organization (WHO) grade 2, the American
Joint Committee on Cancer (AJCC) stage VI (hepatic
metastasis) was conﬁrmed.
The patient had an uneventful recovery following
surgery. Postoperatively, patient received radiofre-
quency ablation for the hepatic lesion. A post-opera-
tive six-month follow-up showed signiﬁcant
symptomatic relief, reduced VIP hormone level
(71 pg/mL) and normalized electrolyte and acid–base
proﬁles. However, a magnetic resonance imaging
(MRI) scan showed a small residual metastatic hepa-
tic lesion, which was considered for hepatic artery
embolization (HAE). The patient is still alive with
residual hepatic disease at 18 months.DISCUSSION
VIPoma is also known as VIPoma syndrome, pancre-
atic cholera syndrome, Verner-Morrison syndrome,
and the WDHA syndrome (watery diarrhea, hypoka-
lemia, and hypochlorhydria or achlorhydria).1
VIPoma is an exceedingly unusual neuroendocrine
neoplasm that autonomously secretes VIP. Its
reported incidence is 1 per 10 million individuals
per year.2
The majority of VIPomas happen sporadically as
isolated pancreatic neoplasms. However, roughly 5%
of VIPomas occur in conjunction with multiple endo-
crine neoplasia type 1 (MEN-1).1
Almost all VIPomas (90%) originate from pancre-
atic tissues (in adults) whereas the remaining 10%
originate from extra-pancreatic tissues (in pediatrics)
such as bronchus, colon, liver, and neuralatol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.com
Fig. 2. Microscopic examination of the resected pancreatic mass. (A) Tumor cells are arranged in solid sheets or cord-like patterns separated by
fibrovascular stroma (magnification power, 10·). (B) Tumor cells are made of relatively uniform intermediate-sized cuboidal cells with centrally
located nuclei, stippled (salt-and-pepper) chromatin outline, and delicately granular eosinophilic cytoplasm (magnification power, 40·).
SPORADIC PANCREATIC VIPOMA case reportcrest-derived tissues (sympathetic nerve chains, pitui-
tary, thyroid and adrenal glands).3
Diagnosis of VIPoma is characteristically delayed.4
Around 60–80% of VIPomas have already metasta-
sized by the time of clinical diagnosis.5 Although
the liver is the most common site of metastasis, lymph
nodes, lungs, and kidneys have also been reported.6
Clinically, VIPoma patients typically present with
watery diarrhea, hypokalemia, and hypochlorhydria
or achlorhydria (WDHA) syndrome.7 TheseHematol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.commanifestations are induced by VIP secretion that
stimulates intestinal cyclic adenosine monophosphate
(cAMP) production, which in turn promotes water
and electrolyte secretion into lumen, resulting in copi-
ous watery diarrhea, drastic electrolyte disturbances,
and radical acid–base imbalances.7 The diarrhea is
characterized by being chronic, profuse, secretary,
unaffected by fasting, exceeding 3 L/day, odorless,
tea-colored, blood-free, mucus-free, high-sodium con-
centrated, and with low osmolal gap.3111
Fig. 3. Immunohistochemical examination of the resected pancreatic mass (magnification power, 40·). (A) Tumor cells stained positive for
chromogranin A. (B) Tumor cells stained positive for synaptophysin. (C) Tumor cells stained positive for vasoactive intestinal peptide (VIP). (D) Tumor
cells stained positive for somatostatin. (E) Tumor cells stained positive for ki-67 (17%).
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case report SPORADIC PANCREATIC VIPOMAHypokalemia can be attributed to: (1) VIPoma-
induced chronic plentiful diarrhea, (2) aldosterone
production, or (3) direct potassium secretion by intes-
tinal absorptive cells (enterocytes).4 Symptoms related
to hypokalemia may include muscle weakness, ﬂaccid
paralysis, abdominal muscle cramps, respiratory
depression, and ECG-changes (ﬂattened T-waves).
In addition to potassium loss in stool, there is also
bicarbonate wasting, resulting in hypokalemic non-
anion gap metabolic acidosis.8 Hypochlorhydria or
achlorhydria is thought to occur due to theHemVIP-induced inhibitory effect on gastric mucosa pari-
etal cells, resulting in decreased gastric acid produc-
tion.9 Hypo- or achlorhydria can lead to various
dietary deﬁciencies secondary to malabsorption of
basic electrolytes (e.g., magnesium, zinc) and vitamins
(e.g., Vitamin C, K and B family).
Other reported symptoms associated with
VIPoma include: facial ﬂushing, skin rash, bloating,
indigestion, nausea, vomiting, backache, lethargy,
and documented unintentional weight loss.10 Dehy-
dration with unreplenished volume loss can lead toatol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.com
Fig 3. (continued)
SPORADIC PANCREATIC VIPOMA case reportpotential renal failure and possibly death – if VIPoma
is left unmanaged.3
Blood laboratory ﬁndings most often reveal ele-
vated plasma VIP levels (60–2100 pg/mL; greater
than 200 pg/mL is diagnostic),10 hypokalemia, hypo-
chlorhydria or achlorhydria, non-anion gap metabolic
acidosis, hyperglycemia and hypercalcemia.8
Pathophysiological mechanisms of hyperglycemia
and hypercalcemia are inadequately understood.
However, the hypercalcemia in MEN-1-associated
VIPomas can be broadly attributed to the hyperpara-
thyroidism component of MEN-1 syndrome.Hematol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.comElevated serum blood urea nitrogen (BUN) and creat-
inine levels can happen due to the marked VIPoma-
induced dehydration (diarrhea) and resultant renal
insufﬁciency/failure.
As the vast majority of pancreatic VIPomas are
located in the pancreatic tail (75%) and are greater
than 3 cm in diameter at the time of clinical pre-
sentation, the neoplastic masses can be straightfor-
wardly identiﬁed by CT scan.11 MRI has a
reported sensitivity of 75–100% in diagnosing
pancreatic neoplasms,12 and can localize neoplasms
as small as 1 cm in diameter.12 As nearly113
Fig 3. (continued)
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case report SPORADIC PANCREATIC VIPOMA80–90% of all VIPomas are somatostatin receptor-
positive, octreoscan scintigraphy is an extremely
helpful radiological intervention, although it is
rarely used.13 Intraoperative ultrasonography
(IOUS) is useful in the detection of obscure neo-
plasms that are not visible with the preoperative
conventional imaging modalities.14
Histopathologically,15 VIPomas are classical neu-
roendocrine tumors. Immunohistochemically,15
VIPomas stain positively for VIP, chromogranin A,
synaptophysin, somatostatin, neuron speciﬁc enolase,
and cytokeratin.
Surgical resection, whenever possible, is the gold
standard of management in patients with primary
and secondary (metastatic) VIPoma disease4,14 and
has been shown to effectively ameliorate symptoms
and prolong disease-free survival.9
Medical (non-surgical) treatment is indicated for
symptomatic relief of diarrhea (palliation) in individuals
unwilling to undergo surgery or presenting with inoper-
able metastatic diseases. Octreotide (somatostatin
analogue) has been shown to greatly control diarrhea,
reduce VIP hormonal levels and stabilize VIPoma
tumor growth (anti-proliferative properties).16
Chemotherapy has been utilized in limited series
of unresectable metastatic diseases with varying
success rates. Doxorubicin/streptozocin is theHemrecommended combination regimen.17 A 5-ﬂuoroura-
cil/streptozocin combination regimen can be consid-
ered whenever doxorubicin is contraindicated.17
Prognosis of VIPoma is largely dependent
on VIPoma tumor grading, staging and surgical
resectability.18 Poor prognostic factors include: age
less than 40 years and more than 60 years, tumor size
more than 4 cm in diameter, poor management of
water, electrolyte and acid–base proﬁles, presence of
metastases, poor tumor differentiation, positive telo-
merase activity, and tumor surgical unresectability.19
Patients with surgically benign resected tumors and
without distant metastases have extremely favorable
prognosis, with a reported ﬁve-year survival rate of
nearly 95%.20 Conversely, patients with distant metas-
tases have an estimated ﬁve-year survival rate of
approximately 60%.20 Morbidity/mortality of
VIPoma results from untreated WDHA syndrome
leading to long-standing dehydration with severe elec-
trolyte and acid–base imbalances, and possibly result-
ing in renal failure. Renal failure, in turn, if left
untreated, may cause cardiac arrest and eventually
death.CONFLICTS OF INTEREST
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